Journal
CELLS
Volume 10, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/cells10092361
Keywords
tumor microenvironment; cancer stem cells; immunogenicity; immune escape; immunotherapy
Categories
Funding
- Associazione Italiana Ricerca sul Cancro (AIRC) [18418]
- Ministero Italiano della Salute [RF_GR-2013-02357273]
- AIRC/FIRC 2020 fellowship [25558]
- Ministero Italiano della Salute grant [RF_GR-2013-02357273]
Ask authors/readers for more resources
Cancer stem cells (CSCs) have the ability to evade immune surveillance and are located at the apex of tumor aggressiveness and therapy resistance. Understanding the immunobiology of CSCs is crucial for identifying new therapeutic opportunities in cancer treatment.
Cancer stem cells (CSCs) are broadly considered immature, multipotent, tumorigenic cells within the tumor mass, endowed with the ability to self-renew and escape immune control. All these features contribute to place CSCs at the pinnacle of tumor aggressiveness and (immune) therapy resistance. The immune privileged status of CSCs is induced and preserved by various mechanisms that directly affect them (e.g., the downregulation of the major histocompatibility complex class I) and indirectly are induced in the host immune cells (e.g., activation of immune suppressive cells). Therefore, deeper insights into the immuno-biology of CSCs are essential in our pursuit to find new therapeutic opportunities that eradicate cancer (stem) cells. Here, we review and discuss the ability of CSCs to evade the innate and adaptive immune system, as we offer a view of the immunotherapeutic strategies adopted to potentiate and address specific subsets of (engineered) immune cells against CSCs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available